FZD4抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 50 μg, Lane: Mouse heart tissue, Primary antibody: P07719(FZD4 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

FZD4 antibodies target Frizzled-4 (FZD4), a member of the Frizzled receptor family that functions as a receptor for Wnt signaling pathways. FZD4 is a seven-transmembrane domain protein critical for regulating both canonical (Wnt/β-catenin) and non-canonical Wnt signaling. It plays essential roles in embryonic development, cell proliferation, tissue homeostasis, and angiogenesis. Dysregulation of FZD4 is implicated in diseases such as cancer, retinopathy, and familial exudative vitreoretinopathy (FEVR), where mutations in FZD4 disrupt retinal vascularization.

FZD4 antibodies are widely used in research to detect FZD4 expression, localization, and function in biological systems. They enable studies on FZD4's interaction with Wnt ligands (e.g., Wnt3a, Wnt5a) and co-receptors like LRP5/6. as well as its role in pathological angiogenesis and tumorigenesis. These antibodies are essential tools in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Some studies highlight FZD4 upregulation in cancers (e.g., breast, colorectal) and its association with poor prognosis, driving interest in FZD4-targeted therapies. Additionally, FZD4 antibodies aid in exploring therapeutic strategies, including blocking antibodies or small molecules to inhibit oncogenic Wnt signaling.

Available as monoclonal or polyclonal forms, FZD4 antibodies are validated for specificity across species, facilitating translational research. Their development continues to advance understanding of Wnt-related pathologies and potential diagnostic or therapeutic applications.